Last Updated : April 27, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Perjeta-Herceptin Combo Pack | Pertuzumab-Trastuzumab Combo Pack | Early Breast Cancer | Do not reimburse | Complete | ||
| Erleada | Apalutamide | non-metastatic castrate resistant prostate cancer (nm-CRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Dysport Therapeutic | abobotulinumtoxinA | lower limb spasticity | Reimburse with clinical criteria and/or conditions | Complete | ||
| Duodopa | Levodopa / carbidopa (Drug Plan Submission) | Parkinson's disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Orkambi | lumacaftor/ivacaftor | Cystic Fibrosis, F508del CFTR mutation in patients 6 years and older | Do not reimburse | Complete | ||
| Fasenra | benralizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Spinraza | Nusinersen | Spinal Muscular Atrophy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Jublia | efinaconazole | Onychomycosis | Do not reimburse | Complete | ||
| Vizimpro | Dacomitinib | Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tafinlar & Mekinist in combo | Dabrafenib & Trametinib in combo | Melanoma Adjuvant Therapy | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 27, 2024